2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3369 Cardiovascular outcomes with venetoclax plus hypomethylating agents in acute myeloid leukemia: A real-world propensity-matched cohort study

Sukul Khanna, Hema Hotchandani, MBBS2, Rishit Gupta3, Priyanshi Maurya, MBBS4, Varshini Srinivasan, MBBS5, Vishnu Sudhakaran, MD6, Ujjwal Soni, Internal Medicine Resident7
1 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
2 SUNY Upstate Medical University, Syracuse, United States
3 University College of Medical Sciences, New Delhi, New Delhi, India
4 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
5 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
6 University of Missouri - Kansas City (UMKC) School of Medicine, KANSAS CITY, United States
7 University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Introduction: Venetoclax plus a hypomethylating agent (HMA) is standard first-line therapy for adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy. This population is old and comorbid from a cardiovascular viewpoint, yet VIALE-A excluded patients with significant cardiac disease, and the cardiovascular (CV) consequences of adding venetoclax to HMA in routine practice are undefined. We compared cardiovascular and bleeding events between venetoclax + HMA versus HMA alone.

Methods: We performed a retrospective propensity-matched cohort study in the TriNetX Global Collaborative Network (180 healthcare organizations). Adults aged 18 years or older with AML (ICD-10 C92.0, C92.00-C92.02, C92.5, C92.6, C92.A) recorded between January 2019 and July 2026 were eligible; acute promyelocytic leukemia and any prior cytarabine, daunorubicin, or idarubicin were excluded. Cohort 1 received venetoclax with azacitidine or decitabine within 1 month before or after venetoclax and cohort 2 received azacitidine or decitabine with no venetoclax exposure. Index was the first qualifying regimen. Cohorts were matched 1:1 on age, sex, ethnicity, hypertension, ischemic heart disease, cerebrovascular disease, heart failure (HF), atrial fibrillation or flutter (AF), chronic kidney disease, diabetes, obesity, hyperlipidemia, myelodysplastic syndrome (MDS), anticoagulants, antiplatelets, beta-blockers, ACE inhibitors, statins, and pre-index creatinine, hemoglobin, platelets, and lymphocyte percentage. Outcomes over days 1-180, 1-365, and 1-1095 were a composite CV endpoint (myocardial infarction, ischemic stroke, HF, cardiac arrest); AF; HF; and bleeding (gastrointestinal hemorrhage, acute posthemorrhagic anemia, intracranial hemorrhage). Risk ratios (RR) and Kaplan-Meier hazard ratios (HR) with 95% confidence intervals were calculated.

Results: 7,483 venetoclax + HMA and 3,571 HMA patients were identified; 3,203 per arm matched for the 180- and 365-day windows and 3,195 per arm for the 1095-day window. Matched cohorts were balanced (all categorical standardized differences <0.03) with a mean age of 69.7 vs 69.8 years, 59% male, hypertensive 56%, ischemic heart disease 27%, MDS 48%, HF 18%, AF 17%, ad 52% using anticoagulants. Cardiovascular outcomes did not differ at any horizon. At 180 days, composite CV events occurred in 23.3% vs 21.6% (RR 1.08, 0.98-1.18), AF in 18.5% vs 17.3% (RR 1.07, 0.96-1.19), HF in 18.3% vs 16.8% (RR 1.09, 0.98-1.22), and bleeding events in 9.7% vs 9.5% (RR 1.02, 0.88-1.19). At 365 days, values were 27.0% vs 25.4% (RR 1.06, 0.98-1.15), 20.6% vs 19.9% (RR 1.04, 0.94-1.14), 20.9% vs 19.5% (RR 1.07, 0.97-1.18), and 12.5% vs 12.5% (RR 1.00, 0.88-1.14). At 1095 days, values were 29.3% vs 29.3% (RR 1.00, 0.93-1.08), 21.9% vs 22.2% (RR 0.99, 0.90-1.08), 21.9% vs 22.4% (RR 0.98, 0.89-1.07), and 14.0% vs 15.7% (RR 0.89, 0.79-1.00).

Conclusions: In a large matched real-world cohort, adding venetoclax to HMA was not associated with excess cardiovascular events, atrial fibrillation, heart failure, or bleeding through 3 years, supporting cardiovascular tolerability in an older, comorbid population which is usually under-represented in registration trials. Prospective studies and disease-specific registries incorporating molecular risk stratification and baseline cardiovascular profiling will be needed to understand the true incremental benefit of adding venetoclax.

 

Sukul Khanna: No relevant conflicts of interest to declare.